[Dilzem-retard efficiency in patients with ischemic heart disease and heart failure].
Effectiveness of a prolonged form of diltiazem was studied in 20 patients with stable effort angina and chronic cardiac failure (NYHA functional class II). Dilcem-retard was given in a dose 180 mg/day for 6 months. Clinical condition, exercise tolerance, left ventricular functional and geometric parameters, heart rhythm variability, late potentials, Holter monitoring evidence were assessed before and after the treatment. Dilcem-retard improved the patients' condition, exercise tolerance, promoted normalization of left ventricular diastolic function, had no negative influence on cardiac output, reduced occurrence of sympathicotonia and late potentials.
A N
AN
Gadzhiev
D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004110:Diltiazem / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D004110:Diltiazem; D001241:Aspirin